Combination therapy comprising cloretazine
View Patent ↗This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with effective amounts of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. The present invention relates to the treatment of cancer, comprising administering to a subject in need thereof an effective amount of VNP40101M in combination with a nucleoside.
1. A composition comprising a dosage of 5 mg/kg to 10 mg/kg of 1,2-Bis-(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)-hydrazine (VNP40101M) and a dosage of about 50 mg/kg of cytarabine, wherein the VNP40101M and cytarabine produce synergistic effects when used in combination in treating tumor.
2. A composition comprising a dosage of 5 mg/kg to 10 mg/kg of VNP40101M and a dosage of about 70 mg/kg of fludarabine, wherein the VNP40101M and fludarabine produce synergistic effects when used in combination in treating tumor.
3. A method of treating tumor in a subject, comprising the step of administering to the subject 5 mg/kg to 10 mg/kg of VNP40101M and about 50 mg/kg cytarabine, wherein the amounts of VNP40101M and cytarabine administered provide, a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or cytarabine individually.
4. The method of claim 3 , wherein the tumor is solid malignant tumor, leukemia or lymphoma.
5. The method of claim 3 , wherein VNP40101M and cytarabine are administered concurrently or sequentially.
6. The method of claim 3 , wherein VNP40101M and cytarabine are administered intravenously, subcutaneously, or orally.
7. The method of claim 4 , wherein the leukemia is acute myelogenous leukemia.
8. A method of treating tumor in a subject, comprising administering to the subject between 100 and 1000 mg/m 2 of VNP40101M and between 500 and 5000 mg/m 2 cytarabine, wherein the amounts of VNP40101M and cytarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or cytarabine individually.
9. The method of claim 3 , wherein the subject is a human.
10. A method of treating tumor in a subject, comprising the step of administering to the subject 5 mg/kg to 10 mg/kg VNP40101M and about 70 mg/kg fludarabine, wherein the amounts of VNP40101M and fludarabine administered provide a reduction in tumor growth that is larger than that achieved by administering either VNP40101M or fludarabine individually.
11. The method of claim 10 , wherein the tumor is solid malignant tumor, leukemia or lymphoma.
12. The method of claim 10 , wherein VNP40101M and fludarabine are administered concurrently or sequentially.
13. The method of claim 10 , wherein VNP40101M and fludarabine are administered intravenously, subcutaneously, or orally.
14. The method of claim 11 , wherein the leukemia is acute myelogenous leukemia.
15. The method of claim 10 , wherein the subject is a human.